No Data
Jinyu Bio-Technology (600201.SH): Collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform.
On December 27, Gelonghui reported that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company has collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform. This effort aims to position themselves early in the fourth generation vaccine—digital vaccines, gradually establishing a complete system from database construction, AI computing power, vaccine design, animal testing validation, to vaccine registration and industrialization. On one hand, AI deep learning models will be utilized to enhance the development and application of animal health products, while on the other hand, the animal health industry’s large-scale data generation capability will be leveraged to continuously optimize AI large models at various stages of vaccine research and development.
CHINARES PHARMA (03320) subsidiary CHINARES PHARMA Holdings' Shareholding in China Resources Boya Bio-pharmaceutical Group has reached 1%.
CHINARES PHARMA (03320) announced that between November 8, 2024, and December 18, 2024, public...
Jinyu Bio-technology Gets China Approval for Cattle Infection Treatment
Tianjin Ringpu Bio-Technology (300119.SZ) plans to change the company name to Tianjin Ringpu Bio-Technology Co., Ltd.
Tianjin Ringpu Bio-Technology (300119.SZ) announced that the company plans to change its Chinese name from “Tianjin Ringpu Bio-Technology Co., Ltd...”
Jinyu Bio-Technology (600201.SH): The business has not yet involved in the digital economy.
Gelonghui reported on December 13 that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company’s business has not yet involved the digital economy sector.
Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) P/E Still Appears To Be Reasonable
Positive Earnings Growth Hasn't Been Enough to Get Jinyu Bio-technology (SHSE:600201) Shareholders a Favorable Return Over the Last Three Years
